|Classification and external resources|
|Toxic liver disease
Toxin induced liver disease
Toxin induced hepatitis
Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage.
The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents. Certain medicinal agents, when taken in overdoses and sometimes even when introduced within therapeutic ranges, may injure the organ. Other chemical agents, such as those used in laboratories and industries, natural chemicals (e.g., microcystins) and herbal remedies can also induce hepatotoxicity. Chemicals that cause liver injury are called hepatotoxins.
More than 900 drugs have been implicated in causing liver injury and it is the most common reason for a drug to be withdrawn from the market. Hepatotoxicity and drug-induced liver injury also account for a substantial number of compound failures, highlighting the need for drug screening assays, such as stem cell-derived hepatocyte-like cells, that are capable of detecting toxicity early in the drug development process. Chemicals often cause subclinical injury to the liver, which manifests only as abnormal liver enzyme tests. Drug-induced liver injury is responsible for 5% of all hospital admissions and 50% of all acute liver failures.
- 1 Cause
- 2 Mechanism of damage
- 3 Diagnosis
- 4 Treatment and prognosis
- 5 Drugs withdrawn
- 6 See also
- 7 References
- 8 External links
Drugs or toxins that have a pharmacological (type A) hepatotoxicity are those that have predictable dose-response curves (higher concentrations cause more liver damage) and well characterized mechanisms of toxicity, such as directly damaging liver tissue or blocking a metabolic process. As in the case of acetaminophen overdose, this type of injury occurs shortly after some threshold for toxicity is reached.
Idiosyncratic (type B) injury occurs without warning, when agents cause non-predictable hepatotoxicity in susceptible individuals, which is not related to dose and has a variable latency period. This type of injury does not have a clear dose-response nor temporal relationship, and most often does not have predictive models. Idiosyncratic hepatotoxicity has led to the withdrawal of several drugs from market even after rigorous clinical testing as part of the FDA approval process; Troglitazone (Rezulin) and trovafloxacin (Trovan) are two prime examples of idiosyncratic hepatotoxins pulled from market.
When used orally, ketoconazole has been associated with hepatic toxicity, including some fatalities.
Acetaminophen (in the US and Japan), paracetamol (INN), also known by the brand name Tylenol and Panadol, is usually well tolerated in prescribed dose, but overdose is the most common cause of drug-induced liver disease and acute liver failure worldwide. Damage to the liver is not due to the drug itself but to a toxic metabolite (N-acetyl-p-benzoquinone imine (NAPQI)) produced by cytochrome P-450 enzymes in the liver. In normal circumstances, this metabolite is detoxified by conjugating with glutathione in phase 2 reaction. In an overdose, a large amount of NAPQI is generated, which overwhelms the detoxification process and leads to liver cell damage. Nitric oxide also plays a role in inducing toxicity. The risk of liver injury is influenced by several factors including the dose ingested, concurrent alcohol or other drug intake, interval between ingestion and antidote, etc. The dose toxic to the liver is quite variable from person to person and is often thought to be lower in chronic alcoholics Measurement of blood level is important in assessing prognosis, higher levels predicting a worse prognosis. Administration of Acetylcysteine, a precursor of glutathione, can limit the severity of the liver damage by capturing the toxic NAPQI. Those that develop acute liver failure can still recover spontaneously, but may require transplantation if poor prognostic signs such as encephalopathy or coagulopathy is present (see King's College Criteria).
Nonsteroidal anti-inflammatory drugs
Although individual analgesics rarely induce liver damage due to their widespread use, NSAIDs have emerged as a major group of drugs exhibiting hepatotoxicity. Both dose-dependent and idiosyncratic reactions have been documented. Aspirin and phenylbutazone are associated with intrinsic hepatotoxicity; idiosyncratic reaction has been associated with ibuprofen, sulindac, phenylbutazone, piroxicam, diclofenac and indomethacin.
Glucocorticoids are so named due to their effect on the carbohydrate mechanism. They promote glycogen storage in the liver. An enlarged liver is a rare side-effect of long-term steroid use in children. The classical effect of prolonged use both in adult and paediatric population is steatosis.
Isoniazide (INH) is one of the most commonly used drugs for tuberculosis; it is associated with mild elevation of liver enzymes in up to 20% of patients and severe hepatotoxicity in 1-2% of patients.
Other hydrazine derivative drugs
There are also cases where other hydrazine derivative drugs, such as the MAOI antidepressant iproniazid, are associated with liver damage. Phenelzine has been associated with abnormal liver tests.
Examples include: Ackee fruit, Bajiaolian, Camphor, Copaltra, Cycasin, Garcinia, Kava leaves, pyrrolizidine alkaloids, Horse chestnut leaves, Valerian, Comfrey. Chinese herbal remedies: Jin Bu Huan, Ma-huang, Shou Wu Pian, Bai Xian Pi.
Mechanism of damage
drug induced hepatotoxicity
Drugs continue to be taken off the market due to late discovery of hepatotoxicity. Due to its unique metabolism and close relationship with the gastrointestinal tract, the liver is susceptible to injury from drugs and other substances. 75% of blood coming to the liver arrives directly from gastrointestinal organs and then spleen via portal veins that bring drugs and xenobiotics in near-undiluted form. Several mechanisms are responsible for either inducing hepatic injury or worsening the damage process. Many chemicals damage mitochondria, an intracellular organelle that produces energy. Its dysfunction releases excessive amount of oxidants that, in turn, injure hepatic cells. Activation of some enzymes in the cytochrome P-450 system such as CYP2E1 also lead to oxidative stress. Injury to hepatocyte and bile duct cells lead to accumulation of bile acid inside the liver. This promotes further liver damage. Non-parenchymal cells such as Kupffer cells, fat storing stellate cells, and leukocytes (i.e. neutrophil and monocyte) also have a role in the mechanism.
Drug metabolism in liver
The human body identifies almost all drugs as foreign substances (i.e. xenobiotics) and subjects them to various chemical processes (i.e. metabolism) to make them suitable for elimination. This involves chemical transformations to (a) reduce fat solubility and (b) to change biological activity. Although almost all tissues in the body have some ability to metabolize chemicals, smooth endoplasmic reticulum in the liver is the principal "metabolic clearing house" for both endogenous chemicals (e.g., cholesterol, steroid hormones, fatty acids, proteins) and exogenous substances (e.g., drugs, alcohol). The central role played by liver in the clearance and transformation of chemicals makes it susceptible to drug-induced injury.
Drug metabolism is usually divided into two phases: phase 1 and phase 2. Phase 1 reaction is thought to prepare a drug for phase 2. However many compounds can be metabolized by phase 2 directly. Phase 1 reaction involves oxidation, reduction, hydrolysis, hydration and many other rare chemical reactions. These processes tend to increase water solubility of the drug and can generate metabolites that are more chemically active and potentially toxic. Most of phase 2 reactions take place in cytosol and involve conjugation with endogenous compounds via transferase enzymes. Chemically active phase 1 products are rendered relatively inert and suitable for elimination by this step.
A group of enzymes located in the endoplasmic reticulum, known as cytochrome P-450, is the most important family of metabolizing enzymes in the liver. Cytochrome P-450 is the terminal oxidase component of an electron transport chain. It is not a single enzyme, but rather consists of a closely related family of 50 isoforms; six of them metabolize 90% of drugs. There is a tremendous diversity of individual P-450 gene products, and this heterogeneity allows the liver to perform oxidation on a vast array of chemicals (including almost all drugs) in phase 1. Three important characteristics of the P-450 system have roles in drug-induced toxicity:
- 1. Genetic diversity:
Each of the P-450 proteins is unique and accounts (to some extent) for the variation in drug metabolism between individuals. Genetic variations (polymorphism) in P-450 metabolism should be considered when patients exhibit unusual sensitivity or resistance to drug effects at normal doses. Such polymorphism is also responsible for variable drug response among patients of differing ethnic backgrounds.
|Potent inducers||Potent inhibitors||Substrates|
(St John's wort),
- 2. Change in enzyme activity:
Many substances can influence the P-450 enzyme mechanism. Drugs interact with the enzyme family in several ways. Drugs that modify cytochrome P-450 enzyme are referred to as either inhibitors or inducers. Enzyme inhibitors block the metabolic activity of one or several P-450 enzymes. This effect usually occurs immediately. On the other hand, inducers increase P-450 activity by increasing its synthesis. Depending on the inducing drug's half life, there is usually a delay before enzyme activity increases.
- 3. Competitive inhibition:
Some drugs may share the same P-450 specificity and thus competitively block their bio transformation. This may lead to accumulation of drugs metabolized by the enzyme. This type of drug interaction may also reduce the rate of generation of toxic substrate.
Patterns of injury
|Type of injury:||Hepatocellular||Cholestatic||Mixed|
|ALT||≥ Twofold rise||Normal||≥ Twofold rise|
|ALP||Normal||≥ Twofold rise||≥ Twofold rise|
|ALT: ALP ratio||High, ≥5||Low, ≤2||2-5|
Chemicals produce a wide variety of clinical and pathological hepatic injury. Biochemical markers (e.g. alanine transferase, alkaline phosphatase and bilirubin) are often used to indicate liver damage. Liver injury is defined as a rise in either (a) ALT level more than three times of upper limit of normal (ULN), (b) ALP level more than twice ULN, or (c) total bilirubin level more than twice ULN when associated with increased ALT or ALP. Liver damage is further characterized into hepatocellular (predominantly initial Alanine transferase elevation) and cholestatic (initial alkaline phosphatase rise) types. However they are not mutually exclusive and mixed types of injuries are often encountered.
Specific histo-pathological patterns of liver injury from drug-induced damage are discussed below.
This is the most common type of drug-induced liver cell necrosis where the injury is largely confined to a particular zone of the liver lobule. It may manifest as a very high level of ALT and severe disturbance of liver function leading to acute liver failure.
In this pattern, hepatocellular necrosis is associated with infiltration of inflammatory cells. There can be three types of drug-induced hepatitis. (A) viral hepatitis is the most common, where histological features are similar to acute viral hepatitis. (B) in focal or non-specific hepatitis, scattered foci of cell necrosis may accompany lymphocytic infiltration. (C) chronic hepatitis is very similar to autoimmune hepatitis clinically, serologically, and histologically.
- (a) Viral hepatitis: Halothane, isoniazid, phenytoin
- (b) Focal hepatitis: Aspirin
- (c) Chronic hepatitis: Methyldopa, diclofenac
Liver injury leads to impairment of bile flow and cases are predominated by itching and jaundice. Histology may show inflammation (cholestatic hepatitis) or it can be bland (without any parenchymal inflammation). On rare occasions, it can produce features similar to primary biliary cirrhosis due to progressive destruction of small bile ducts (Vanishing duct syndrome).
- (a) Bland: Oral contraceptive pills, anabolic steroid, androgens
- (b) Inflammatory: Allopurinol, co-amoxiclav, carbamazepine
- (c) Ductal: Chlorpromazine, flucloxacillin
Hepatotoxicity may manifest as triglyceride accumulation, which leads to either small-droplet (microvesicular) or large-droplet (macrovesicular) fatty liver. There is a separate type of steatosis by which phospholipid accumulation leads to a pattern similar to the diseases with inherited phospholipid metabolism defects (e.g., Tay-Sachs disease)
- (a) Microvesicular: Aspirin (Reye's syndrome), ketoprofen, tetracycline (especially if expired)
- (b) Macrovesicular: Acetamenophen, methotrexate
- (c) Phospholipidosis: Amiodarone, total parenteral nutrition
Drug-induced hepatic granulomas are usually associated with granulomas in other tissues and patients typically have features of systemic vasculitis and hypersensitivity. More than 50 drugs have been implicated.
These result from injury to the vascular endothelium.
- Venoocclusive disease: Chemotherapeutic agents, bush tea
- Peliosis hepatis: Anabolic steroids
- Hepatic vein thrombosis: Oral contraceptives
Neoplasms have been described with prolonged exposure to some medications or toxins. Hepatocellular carcinoma, angiosarcoma, and liver adenomas are the ones usually reported.
This remains a challenge in clinical practice due to a lack of reliable markers. Many other conditions lead to similar clinical as well as pathological pictures. To diagnose hepatotoxicity, a causal relationship between the use of the toxin or drug and subsequent liver damage has to be established, but might be difficult, especially when idiosyncratic reaction is suspected. Simultaneous use of multiple drugs may add to the complexity. As in acetaminophen toxicity, well established, dose-dependent, pharmacological hepatotoxicity is easier to spot. Several clinical scales such as CIOMS/RUCAM scale and Maria and Victorino criteria have been proposed to establish causal relationship between offending drug and liver damage. CIOMS/RUCAM scale involves a scoring system that categorizes the suspicion into "definite or highly probable" (score > 8), “probable” (score 6-8), “possible” (score 3-5), “unlikely” (score 1-2) and “excluded” (score ≤ 0). In clinical practice, physicians put more emphasis on the presence or absence of similarity between the biochemical profile of the patient and known biochemical profile of the suspected toxicity (e.g., cholestatic damage in amoxycillin-clauvonic acid ).
Treatment and prognosis
In most cases, liver function will return to normal if the offending drug is stopped early. Additionally, the patient may require supportive treatment. In acetaminophen toxicity, however, the initial insult can be fatal. Fulminant hepatic failure from drug-induced hepatotoxicity may require liver transplantation. In the past, glucocorticoids in allergic features and ursodeoxycholic acid in cholestatic cases had been used, but there is no good evidence to support their effectiveness.
An elevation in serum bilirubin level of more than 2 times ULN with associated transaminase rise is an ominous sign. This indicates severe hepatotoxicity and is likely to lead to mortality in 10% to 15% of patients, especially if the offending drug is not stopped (Hy's Law). This is because it requires significant damage to the liver to impair bilirubin excretion, hence minor impairment (in the absence of biliary obstruction or Gilbert syndrome) would not lead to jaundice. Other poor predictors of outcome are old age, female sex, high AST.
The following therapeutic drugs were withdrawn from the market primarily because of hepatotoxicity: Troglitazone, bromfenac, trovafloxacin, ebrotidine, nimesulide, nefazodone, ximelagatran and pemoline.
- Friedman, Scott E.; Grendell, James H.; McQuaid, Kenneth R. (2003). Current diagnosis & treatment in gastroenterology. New York: Lang Medical Books/McGraw-Hill. pp. 664–679. ISBN 0-8385-1551-7.
- Greenhough S, Hay DC. (2012). "Stem Cell-Based Toxicity Screening: Recent Advances in Hepatocyte Generation". Pharm Med 26 (2): 85–89. doi:10.1007/BF03256896.
- McNally, Peter F. (2006). GI/Liver Secrets: with STUDENT CONSULT Access. Saint Louis: C.V. Mosby. ISBN 1-56053-618-7.
- Ostapowicz G, Fontana RJ, Schiødt FV, et al. (2002). "Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States". Ann. Intern. Med. 137 (12): 947–54. doi:10.7326/0003-4819-137-12-200212170-00007. PMID 12484709.
- Davies, D. (1985). Textbook of adverse drug reactions. Oxford [Oxfordshire]: Oxford University Press. pp. 18–45. ISBN 0-19-261479-7. OCLC 12558288.
- Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK (1998). "Adverse drug reactions". BMJ 316 (7140): 1295–8. doi:10.1136/bmj.316.7140.1295. PMC 1113033. PMID 9554902.
- Zimmerman HJ (1978). "Drug-induced liver disease". Drugs 16 (1): 25–45. doi:10.2165/00003495-197816010-00002. PMID 352664.
- "Ketoconazole Tablets".
- Keeffe, Emmet B; Friedman, Lawrence M. (2004). Handbook of liver diseases. Edinburgh: Churchill Livingstone. pp. 104–123. ISBN 0-443-06633-7.
- Wallace JL (2004). "Acetaminophen hepatotoxicity: NO to the rescue". Br. J. Pharmacol. 143 (1): 1–2. doi:10.1038/sj.bjp.0705781. PMC 1575258. PMID 15345657.
- James LP, Mayeux PR, Hinson JA (2003). "Acetaminophen-induced hepatotoxicity". Drug Metab. Dispos. 31 (12): 1499–506. doi:10.1124/dmd.31.12.1499. PMID 14625346.
- Riordan SM, Williams R (2002). "Alcohol exposure and paracetamol-induced hepatotoxicity". Addict Biol 7 (2): 191–206. doi:10.1080/13556210220120424. PMID 12006215.
- Prescott, Laurie F. (2000). "Paracetamol, alcohol and the liver". British Journal of Clinical Pharmacology 49 (4): 291–301. doi:10.1046/j.1365-2125.2000.00167.x. PMC 2014937. PMID 10759684.
- Manov I, Motanis H, Frumin I, Iancu TC (2006). "Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects". Acta Pharmacol. Sin. 27 (3): 259–72. doi:10.1111/j.1745-7254.2006.00278.x. PMID 16490160.
- Iancu TC, Shiloh H, Dembo L (1986). "Hepatomegaly following short-term high-dose steroid therapy". J. Pediatr. Gastroenterol. Nutr. 5 (1): 41–6. doi:10.1097/00005176-198601000-00008. PMID 3944744.
- Alpers DH, Sabesin SM (1982). Schiff L; Schiff ER, eds. Diseases of the liver. Philadelphia: JB Lippincott. pp. 813–45.
- Sarich TC, Adams SP, Petricca G, Wright JM (1999). "Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor". J. Pharmacol. Exp. Ther. 289 (2): 695–702. PMID 10215642.
- Schläppi B (1984). "The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid". Arzneimittel-Forschung 35 (5): 800–803.
- Cook G. C., Sherlock S. (1965). "Jaundice and its relation to therapeutic agents". The Lancet 285 (7378): 175–179. doi:10.1016/s0140-6736(65)90969-4.
- Kothari U. C. (1960). "TOXIC AND OTHER SIDE EFFECTS OF NARDIL PHENELZINE SULPHATE W-1544A". American Journal of Psychiatry 116 (8): 746–747. doi:10.1176/ajp.116.8.746.
- Kumar, EP; Kumar, AnilD; Parasuraman, S; Rajan, VijayR; Emerson, SF (2013). "Hepatoprotective activity of Clearliv a polyherbal formulation in Wistar rats". Archives of Medicine and Health Sciences 1 (2): 120–5. doi:10.4103/2321-4848.123023.
- Kim, Young-Je (2013). "Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation". World Journal of Gastroenterology 19 (29): 4689–701. doi:10.3748/wjg.v19.i29.4689. PMC 3732841. PMID 23922466.
- Zhou, P.; Gross, S.; Liu, J.-H.; Yu, B.-Y.; Feng, L.-L.; Nolta, J.; Sharma, V.; Piwnica-Worms, D.; Qiu, S. X. (2010). "Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF- B and MAPK signaling pathways". The FASEB Journal 24 (12): 4722–32. doi:10.1096/fj.10-163311. PMC 2992378. PMID 20696856.
- Pak, E; Esrason, KT; Wu, VH (2004). "Hepatotoxicity of herbal remedies: an emerging dilemma". Progress in Transplantation 14 (2): 91–6. doi:10.7182/prtr.14.2.k7743w3j64855180. PMID 15264453.
- McRae, CA; Agarwal, K; Mutimer, D; Bassendine, MF (2002). "Hepatitis associated with Chinese herbs". European Journal of Gastroenterology & Hepatology 14 (5): 559–62. doi:10.1097/00042737-200205000-00015. PMID 11984156.
- Furukawa, Maiko; Kasajima, Saeko; Nakamura, Yuri; Shouzushima, Meiko; Nagatani, Naho; Takinishi, Akira; Taguchi, Ayumi; Fujita, Mikiko; Niimi, Akiko; Misaka, Ryoichi; Nagahara, Hikaru (2010). "Toxic Hepatitis Induced by Show-Wu-Pian, a Chinese Herbal Preparation". Internal Medicine 49 (15): 1537–40. doi:10.2169/internalmedicine.49.3509. PMID 20686286.
- Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ (2002). "Mechanisms of hepatotoxicity". Toxicol. Sci. 65 (2): 166–76. doi:10.1093/toxsci/65.2.166. PMID 11812920.
- Patel T, Roberts LR, Jones BA, Gores GJ (1998). "Dysregulation of apoptosis as a mechanism of liver disease: an overview". Semin. Liver Dis. 18 (2): 105–14. doi:10.1055/s-2007-1007147. PMID 9606808.
- Donald Blumenthal; Laurence Brunton; Keith Parker; Lazo, John S.; Iain Buxton (2006). Goodman and Gilman's Pharmacological Basis of Therapeutics Digital Edition. McGraw-Hill Professional. ISBN 0-07-146804-8.
- Skett, Paul; Gibson, G. Gordon (2001). Introduction to drug metabolism. Cheltenham, UK: Nelson Thornes Publishers. ISBN 0-7487-6011-3.
- Lynch T, Price A (2007). "The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects". American Family Physician 76 (3): 391–6. PMID 17708140.
- Jessica R. Oesterheld; Kelly L. Cozza; Armstrong, Scott (2003). Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, Ugts, P-Glycoproteins. Washington, DC: American Psychiatric Association. pp. 167–396. ISBN 1-58562-111-0.
- "P450 Table". Retrieved 2007-09-29.
- Michalets EL (1998). "Update: clinically significant cytochrome P-450 drug interactions". Pharmacotherapy 18 (1): 84–112. doi:10.1002/j.1875-9114.1998.tb03830.x. PMID 9469685.
- Mumoli N, Cei M, Cosimi A (2006). "Drug-related hepatotoxicity". N. Engl. J. Med. 354 (20): 2191–3; author reply 2191–3. doi:10.1056/NEJMc060733. PMID 16710915.
- Bénichou C (1990). "Criteria of drug-induced liver disorders. Report of an international consensus meeting". J. Hepatol. 11 (2): 272–6. doi:10.1016/0168-8278(90)90124-A. PMID 2254635.
- Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI (2007). "Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists". World J. Gastroenterol. 13 (3): 329–40. doi:10.3748/wjg.v13.i3.329. PMID 17230599.
- Arundel C, Lewis JH (2007). "Drug-induced liver disease in 2006". Curr. Opin. Gastroenterol. 23 (3): 244–54. doi:10.1097/MOG.0b013e3280b17dfb. PMID 17414839.
- Reuben A (2004). "Hy's law". Hepatology 39 (2): 574–8. doi:10.1002/hep.20081. PMID 14768020.
- Arora N, Goldhaber SZ (2006). "Anticoagulants and transaminase elevation". Circulation 113 (15): e698–702. doi:10.1161/CIRCULATIONAHA.105.603100. PMID 16618822.
- Andrade RJ, Lucena MI, Kaplowitz N, et al. (2006). "Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry". Hepatology 44 (6): 1581–8. doi:10.1002/hep.21424. PMID 17133470.
- Björnsson E, Olsson R (2005). "Outcome and prognostic markers in severe drug-induced liver disease". Hepatology 42 (2): 481–9. doi:10.1002/hep.20800. PMID 16025496.
- Shah RR (1999). "Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction". Adverse drug reactions and toxicological reviews 18 (4): 181–233. PMID 10687025.
- Drug-Induced Hepatotoxicity at eMedicine